Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
240.65
+3.30 (1.39%)
At close: Mar 6, 2026, 4:00 PM EST
240.65
0.00 (0.00%)
After-hours: Mar 6, 2026, 5:03 PM EST
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$711,121
Profits / Employee
-$225,181
Market Cap
14.77B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 4,700 |
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
ASND News
- 2 days ago - Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 3 days ago - Ascendis Pharma: Yuviwel Approved Despite Legal Challenges - Seeking Alpha
- 4 days ago - Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript - Seeking Alpha
- 4 days ago - Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 6 days ago - Ascendis wins U.S. approval for therapy for children with dwarfism - Reuters
- 6 days ago - FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - GlobeNewsWire
- 22 days ago - Ascendis Pharma FY 2025 Results: More Than A Takeover Story - Seeking Alpha
- 22 days ago - Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript - Seeking Alpha